Interview: Denis Delval – Senior Vice President, Europe West and South,…
ALK’s Denis Delval reveals how France is number one in terms of volumes for the group and number two in terms of revenues, just behind Germany; how the four Danes…
Expanscience is a family owned, independent French pharmaceutical and dermo-cosmetics laboratory, developing and manufacturing innovative osteoarthritis and skincare products. The company’s products, including two leading brands including Piascledine 300 and Mustela, are sold in more than 100 countries. With over 60 years of experience, Expanscience has built up a solid international reputation as an innovator and a specialist. The company prides itself in developing and marketing with active ingredients of natural origin for the French and international cosmetics industry. Thanks to a robust Corporate Social Responsibility program introduced over ten years ago, the company has made strong efforts in developing a sustainable and environmentally conscious business practice which has been recognized as exemplary by the AFAQ 26000 assessment in 2013. With a company motto: “Protecting Your Health Through Innovation,” Expanscience innovates to develop safe and effective solutions that do not harm people or the environment so that everyone can avoid osteoarthritis and skin problems.
Contact
10 avenue de l’Arche
92419 – Courbevoie
France
Tel : +33 (0)1 43 34 60 00
ALK’s Denis Delval reveals how France is number one in terms of volumes for the group and number two in terms of revenues, just behind Germany; how the four Danes…
The president and CEO of AREVA Med, the medical subsidiary of AREVA Group, the biggest nuclear company in the world, discusses the circumstances that inspired AREVA’s foray into nuclear medicine,…
The President of CEPS, the French pricing agency, reveals the issues around the launch of the hepatitis C drug Sovaldi in 2014 and of CEPS´ role to ensure that innovative products are available to all…
The President of Innothera talks about their unique business model, being in both the drug production and compression stockings businesses, how almost 95 percent of their drug production is exported,…
Olivier Pilley, French GM of the Swiss-American biotech company with a pioneering computational approach to anti-cancer therapies, presents ARIAD’s fascinating R&D model, his optimistic assessment of the competitiveness of the French…
The Director of the Social Security talks about the need to strengthen the sustainability of the French social security system, how France is attached to its unique system combining a…
The head of Aspen sterile operations and managing director of Aspen NDB, reveals how their facility in France acts as the main platform for the group´s sterile business, a market…
The CEO of Diaxonhit Group, a fully integrated French leader in in vitro diagnostics, discusses the company’s strategic focus on specialty vitro diagnostics, his perspective on the challenge of consolidation…
The Vice President of Health and Medicine at Pierre and Marie Curie University (UPMC) and Director of the University’s Institute of Oncology reveals how the French social security system needs…
The Director of the CNCR and the person in charge of the industrial sector, talk about the fragmented nature of French clinical research funding, why when it comes to boosting…
The President of France’s Association for CROs (AFCROs) discusses the issues surrounding France’s clinical research sector and the actions that both the public and private sector need to take to…
The president of Gedeon Richter France and CEO of PregLem, a Swiss-based biotech company acquired by Gedeon Richter in 2010, discusses the exciting synergies that have emerged from this partnership…
See our Cookie Privacy Policy Here
